RE:Holding up quite wellBig deal, they announced a shelf prospectus, with 25 months to exercise it. They won't go to that until well after they have approval in April. As far as the refocusing, good for them. They know they have to prioritize specific programs to go for commercialization of these applications. Then they can follow up with trials for other drugs and applications. Again, it's no big deal and a smart move. Let's see what comes out of their meetings in NY city.